Overweight or Obesity
150
37
56
65
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Research Maturity
65 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.3%
2 terminated out of 150 trials
97.0%
+10.5% vs benchmark
13%
19 trials in Phase 3/4
14%
9 of 65 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 65 completed trials
Clinical Trials (150)
A Study of SYH2069 Injection in Healthy Participants
A Study of SYH2082 Injection in Healthy Participants
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain
Better Lifestyle Counseling for African American Women During Pregnancy
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
Sleep Extension or Regularity to Reduce Diabetes Risk
Efficacy of Satisens® in Reducing Emotional Eating
Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Hepatic Energy Fluxes in NASH and NAS Patients